Sea breezes and sunshine for Diaceutics cyclists

December 11th, 2017

If you’re going to take part in a charity cycle race for cancer, then where better than California? This was the sunny setting for Ewelina Golebiewska and John McNamara from Diaceutics as they joined Team Pfizer in November 2017 on the two-day Padres Pedal the Cause event.

The scenery was amazing and the atmosphere even better, plus we had super supportive crowds cheering us on, recalled Ewelina. That’s not to say it was easy. An 88-mile hilly ride on the Saturday followed by 66 miles into the coastal head winds the day after is enough to test the strongest cyclist, but they all loved it and were pushed on by adrenaline, excitement, team spirit and a San Diego sea breeze. It was definitely a challenge, especially that one big 600m climb, but what does that matter when you get to cycle across the Coronado bridge on one of only two days a year it’s opened to cyclists? John and Ewelina settled into the Pfizer team like a companion diagnostic fits its therapy, and they all worked together to reach their goal – to raise as much money as possible for cancer research projects in the San Diego area. They certainly achieved that, with the two Diaceutics cyclists adding an impressive $3149 to the cause.

More inspiring than the ocean view though, was the feeling that everyone was doing their bit for cancer research. “The hundreds of people taking part in the race are all directly involved with cancer in their daily lives. They have careers behind the scenes in research, hospitals and big cancer centres, or work directly with patients,” said Ewelina. “It was fantastic to all be doing something so positive outside work as well.”

With 100 per cent of donations going to fund ongoing discoveries in the fight against cancer, Ewelina is already looking forward to her next Team Diaceutics cycling challenge. Well done, from all at Diaceutics.

Webinars & Podcasts

April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
May 25th, 2017
Moving beyond the hype: the reality of NGS in oncology today and in the future
Has Next Generation Sequencing lived up to the hype of industry predictions? Join our next webinar to get a unique insight into the real-world use of NGS in the clinical setting. What are the opportunities and challenges of its implementation and ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


August 29th, 2017
Companion diagnostics driving new model for pharma-Dx partnerships
With a growing number of approvals for companion diagnostics, the pharmaceutical industry is taking keen interest in testing uptake and thinking about steps it can take to further drive testing.
July 3rd, 2017
Pushing forward with precision medicine: how deep data analysis will change the patient journey
An explosion in computational power and vast collections of data are making precision medicine a reality, starting with diagnostics and leading to individualised treatment for patients.
View all publications